Why Vistagen Therapeutics, Inc.’s (VTGN) Stock Is Down 7.41%
As of Thursday, December 18, Vistagen Therapeutics, Inc.’s VTGN share price has dipped by 7.41%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company’s product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women’s health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Commentary & Analysis
Why Vistagen Therapeutics, Inc.’s (VTGN) Stock Is Down 81.23%
As of Wednesday, December 17, Vistagen Therapeutics, Inc.’s VTGN share price has dipped by 81.23%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Vistagen Therapeutics, Inc.’s (VTGN) Stock Is Down 80.42%
As of Wednesday, December 17, Vistagen Therapeutics, Inc.’s VTGN share price has dipped by 80.42%, which has investors questioning if this is right time to buy.Omar Beirat
Why Vistagen Therapeutics, Inc.’s (VTGN) Stock Is Up 6.84%
As of Friday, December 12, Vistagen Therapeutics, Inc.’s VTGN share price has surged by 6.84%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Vistagen Therapeutics, Inc.’s (VTGN) Stock Is Down 5.30%
As of Thursday, December 11, Vistagen Therapeutics, Inc.’s VTGN share price has dipped by 5.30%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | VTGN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $10.8 | $282.4 | 6% |
|
| Shares Out (Mil) | 43.0 | 54.0 | 44% |
|
| Institutional Ownership | 98.5% | 93.1% | 79% |
|
| Float (Mil) | 41.4 | 42.2 | 43% |
|
| Beta | 0.38 | 0.94 | 22% |
|
| Avg Daily Volume (000s) | 442 | 482 | 58% |
|
| Price Change (52-week) |
(93.3%) | 59.9% | 3% |
|
| Growth | VTGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 3.4% | 14.1% | 29% |
|
| Net Income (5yr) | (31.2%) | (10.1%) | 13% |
|
| EPS (5yr) | 34.1% | 15.9% | 84 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.2%) | (15.6%) | 50% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.370) | ($1.450) | ($1.540) | |
| Month Ago EPS | ($0.375) | ($1.475) | ($1.540) | |
| # Rev Up | 3 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($0.243) | ($0.977) | ($1.105) | |
| Year/Year Chg | 22.1% | (20.8%) | (9.3%) | |
| Financials | VTGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3 | $37 | 4% |
|
| Net Income (TTM) (Mil) | ($68) | ($43) | 14% |
|
| EPS (TTM) | ($1.656) | ($1.500) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($62) | ($31) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($32) | $2 | 22% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 10% |
|
| Enterprise Value (Q1) (Mil) | ($20) | $190 | 1% |
|
| Valuation | VTGN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.44 | 2.84 | 7% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | VTGN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 66.9% | 96% |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (129.2%) | (47.7%) | 4% |
|
| ROE | (166.5%) | (55.0%) | 5% |
|
| Liabilities to Assets | 31.5% | 29.8% | 23% |
|
| F-Score | 4 | 3 | 33% |
|
Vistagen Therapeutics, Inc. did not pass any screens on 9/4/2026.
